NCT05235542View on ClinicalTrials.gov

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2024

Conditions
Advanced Malignant Tumors
Interventions
DRUG

AK104

IV infusion,Specified dose on specified days

DRUG

AK117

IV infusion,Specified dose on specified days

DRUG

Capecitabine tablets

Oral,Specified dose on specified days

DRUG

Oxaliplatin

IV infusion,Specified dose on specified days

DRUG

Cisplatin

IV infusion,Specified dose on specified days

DRUG

Paclitaxel

IV infusion,Specified dose on specified days

DRUG

Irinotecan

IV infusion,Specified dose on specified days

DRUG

Docetaxel

IV infusion,Specified dose on specified days

DRUG

5-FU

IV infusion,Specified dose on specified days

Trial Locations (1)

Unknown

RECRUITING

Shanghai Renji Hospital, Shanghai

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT05235542 - A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter